This Article Full Text Full Text (PDF) All Versions of this Article: 91/10/4131    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koeijvoets, K. C. M. C. Articles by Sijbrands, E. J. G. Search for Related Content PubMed PubMed Citation Articles by Koeijvoets, K. C. M. C. Articles by Sijbrands, E. J. G. Related Collections Adrenal and Hypertension Cardiovascular Endocrinology

A Functional Polymorphism in the Glucocorticoid Receptor Gene and Its Relation to Cardiovascular Disease Risk in Familial Hypercholesterolemia

Departments of Internal Medicine (K.C.M.C.K., E.F.C.v.R., G.M.D.-T., S.W.J.L., E.J.G.S.) and Public Health (E.W.S.), Erasmus Medical Center, 3000 AC Rotterdam, The Netherlands; and Department of Vascular Medicine (J.C.D., J.J.P.K.), Academic Medical Center, 1105 AZ Amsterdam, The Netherlands

Address all correspondence and requests for reprints to: Dr. E. J. G. Sijbrands, Department of Internal Medicine, D435, Erasmus Medical Center, P.O. Box 2040, 3000 AC Rotterdam, The Netherlands. E-mail: e.sijbrands{at}erasmusmc.nl.

Context: Individuals with the functional ER22/23EK variant in the glucocorticoid receptor gene are relatively resistant to the downstream consequences of glucocorticoids. Evidence suggests that carriers have a more favorable cardiovascular risk profile, but the relationship between this ER22/23EK variant and cardiovascular disease has not been hitherto assessed.

Objective: We, therefore, determined whether carriership of the ER22/23EK improves cardiovascular disease risk in patients with severe hypercholesterolemia.

Design, Setting, and Participants: In a multicenter cohort study, 2024 patients with heterozygous familial hypercholesterolemia, aged 18 yr and older, were genotyped for the ER22/23EK polymorphism. Patients were identified at lipid clinics throughout The Netherlands between 1989 and 2002.

Main Outcome Measures: The primary outcome measure was cardiovascular disease.

Results: Seventy-six (7.8%) of 977 men and 72 (6.9%) of 1047 women were carriers of the ER22/23EK variant. A total of 395 men and 247 women had a cardiovascular event. In contrast to expected results, we observed no significant association of the ER22/23EK variant with cardiovascular disease risk (men: relative risk, 0.75; 95% confidence interval, 0.50–1.14; P = 0.2; women: relative risk, 1.37; 95% confidence interval, 0.82–2.28; P = 0.2). However, we found a significant interaction between gender and the polymorphism on cardiovascular disease (P = 0.02).

Conclusions: In this large cohort of individuals with very high risk of cardiovascular disease, the association between the functional ER22/23EK polymorphism and cardiovascular risk was not significant overall, although it varied significantly by gender.

This article has been cited by other articles:

				J. B. van der Net, D. M. Oosterveer, J. Versmissen, J. C. Defesche, M. Yazdanpanah, B. E. Aouizerat, E. W. Steyerberg, M. J. Malloy, C. R. Pullinger, J. J.P. Kastelein, et al. Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia Eur. Heart J., September 2, 2008; 29(18): 2195 - 2201. [Abstract] [Full Text] [PDF]